

IMMUNOTHERAPYTM

What's Next for Cancer Immunotherapy?

Thomas U Marron, MD, PhD

Assistant Director, Early Phase and Immunotherapy Trials Tisch Cancer Institute Icahn School of Medicine at Mount Sinai







Society for Immunotherapy of Cancer

Association of Community Cancer Centers



Disclosures

Personal Financial Disclosures

• None

Research Funding

- Bristol-Myers Squibb
- Regeneron
- Merck
- CTI Biopharma

I will be discussing off-label use of novel therapies (no connection to my research)









Quick Review of Immunology 101 Your immune system recognizes self/foreign






© 2018–2019 Society for Immunotherapy of Cancer






Neoantigens: Things that make tumor cells look different from normal cells

Similar to how virally-infected cells look different from normal cells





Quick Review of Immunology 102 How to teach your cells to recognize "foreign" cancer























Tumors Hijack the Immune System

1. Turn off the immune response (e.g. PD-L1)

Tumor cell

2. Recruit cells that suppress the immune response

Tumors recruit accomplices within our immune system

0

0

0

T cell

0

 \bigcirc

0

0

0

0

0

0

12 J Gregory ©2017 Mount Sinai Health System

Neutrophil

or MDSC

0

0

00


0

0


Tumor

neoantigen

Treg cell



Society for Immunotherapy of Cance



© 2018–2019 Society for Immunotherapy of Cancer

Society for Immunotherapy of Cancer




There are almost too many new cancer therapies in development

Tang et al, Nat Rev Drug Discov, Oct 2018; Created on Oct 10, 2018.

Comparison of global IO pipelines of 2017 and 2018



Clinical Accelerator Clinical stage



Number of active IO agents








There is significant redundancy within the field (pros/cons)

273 targets and 2,031 agents in 2017



417 targets and 3,394 agents in 2018









Overview of phase 1 clinical trials















ACCC



Interesting new combinations

- 1) New checkpoints (finding the next PD-1)
- 2) New combinations with PD-1
 - 1) New immune agents
 - 2) Chemotherapy
 - 3) Radiation



- 3) New approaches for people who don't respond to PD-1 (or progress post-response)
- 4) Recruiting other white blood cells to attack cancer





Results from a Phase I dose escalation trial (TACTI-mel) with the soluble LAG-3 protein (IMP321, eftilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma

<u>Adnan Khattak</u>¹, Victoria Atkinson², Andrew Haydon³, Melissa Eastgate⁴, Amitesh Roy⁵, Christian Mueller⁶, Chrystelle Brignone⁷, Frederic Triebel⁷


¹ Fiona Stanley Hospital, Perth ² Princess Alexandra Hospital, Brisbane
³ Alfred Hospital, Melbournen ⁴ Royal Brisbane Womens Hosital, Brisbane
⁵ Flinders Centre for Innovation in Cancer, Adelaide
⁶ Clinical Development Immutep, GmbH, Berlin ⁷ R&D Immutep, Paris



Society for Immunotherapy of Cancer

#SITC2018











© 2018–2019 Society for Immunotherapy of Cancer



eftilagimod alpha (IMP321): APC activator (i.e. not an ICI)



#SITC2018

TACTI-mel: Trial Design

Study Scheme Part A: Combined immunotherapy* PFS FU every 12 wks Screening (9 cycles of pembrolizumab + IMP321) Continuation of pembrolizumab monotherapy Cycle 1-3 of pembrolizumab (patients with sub-optimal response or progressive disease after 3 cycles with pembrolizumab are eligible to the trial) Cycle 4 of Cycle 5-13 of Pembrolizumab* pembro = Cycle 1-9 of TACTI-mel End of End of Enrolment treatment study 18 pts in total → 6 pts per efti dose group

• Patients received:

2018

- o 2 mg/kg pembrolizumab i.v. every 3 weeks
- o 1, 6, 30 mg efti s.c. every 2 weeks for up to 6 months
- Imaging was done every 12 weeks

Society for Immunotherapy of Cancer

#SITC2018

* - tumor assessments done acc. to irRC irRC...Immune-Related Response Criteria, PFSprogression free survival, FU – follow-up

TACTI-mel: Safety Summary

Overview grade 3 / 4 TEAEs and rel. to study treatment

Preferred term	Grade 3 N (%)	Grade 4 N (%)	Rel to efti / pembro
Maculo-papular rash	1 (6 %)	-	No / Yes
Decreased renal function	1 (6 %)	-	Yes / No
Colitis	1 (6 %)	-	No / Yes
Altered liver functions	1 (6 %)	-	No / Yes

· No Dose limiting toxicities observed

2018

- 6 pts (33 %) with ≥ 1 SAE; none related to any study drug
- 8 pts (44 %) with ≥ 1 AE with ≥ grade 3 (no grade 5)



Overview frequent TEAE (PT selected if ≥ 10 % of the pts)

Adverse Event*,	Any grade N (%)	Grade 3 or 4 N (%)	No of events	
Arthralgia	3 <mark>(</mark> 17)	-	3	
Diarrhea	5 <mark>(</mark> 28)	-	6	
Fatigue	8 (44)	-	10	
Hyperglycemia	3 (17)	3 (17)	3	
Nausea	5 (28)	-	7	
Rash##	7 (39)	1 (6)	7	

- No new safety signals
- 1 pt died due to an AE (grade 4 Intercranial hemorrhage, not rel.)
- 1 pt discontinued due to an AE (not rel.)
- 3 pts experienced treatment delay due to an AE

Society for Immunotherapy of Cancer

#SITC2018



preliminary data, status Oct 15th 2018

any kind of rash

32018 TACTI-mel: Baseline Characteristics + Efficacy Summary

Baseline Characteristics	N = 18 (%)		
Age (median)	67 yrs		
Sex (f/m)	1 (6 %) / 17 (94 %)		
Elevated LDH	7 (39%)		
Metastasis stage M1c	14 (78 %)		
Pre-treated with BRAF/MEK/ipilimumab	5 (28 %)		
irPD/irSD to pembro after 3 cycles	11 (61 %)		

Best Overall Response acc. to irRC	N = 18 (%)	
irCR	1 (6 %)	
irPR#	5 (28 %)#	
irSD	6 (33 %)	
irPD	6 (33 %)	
Best overall response rate (ORR)	6 (33 %)	
Patients with tumor shrinkage	10 (56 %)	
Disease control rate	12 (66 %)	

- incl. 1 pt with complete disappearance of all target lesions

 Very late stage of disease (M1c, elevated LDH) and majority not responding to pembrolizumab monotherapy



 If response is calculated from prepembro timepoint → ORR is 61 % acc. to irRC

Society for Immunotherapy of Cancer


#SITC2018



1

preliminary data, status Oct 15th 2018

TACTI-mel: Response patterns




#SITC2018

preliminary data, status Oct 15th 2018


5.2018



- 84 year old male with multiple lung metastases from melanoma
- BRAF wild type



week 64 (PFS-FU)



preliminary data, status Oct 15th 2018

- Patient progressing on pembrolizumab monotherapy
- At 1 yr all lesions disappeared → CR (confirmed)
- Patient without treatment and disease free → now lost to FU



Society for Immunotherapy of Cancer

#SITC2018





Phase 2 Trial of Mocetinostat in Combination with Durvalumab in NSCLC Patients (Pts) with Progression on Prior Checkpoint Inhibitor Therapy


Melissa Johnson¹,Keith D. Eaton², Balazs Halmos³, Edward Garon⁴, Thomas Hensing⁵, Nisha A. Mohindra⁶, James Strauss⁷, Timothy McCarthy⁸, Rami Owera⁹, Isan Chen¹⁰, Peter Olson¹⁰, Demiana Faltaos¹⁰, James Christensen¹⁰, Diane Potvin¹⁰, Tavette Neskorik¹⁰, Adam Pavlicek¹¹, Manish Patel¹²

 ¹Sarah Cannon Research Institute, Nashville, TN, USA, ²Seattle Cancer Care Alliance, Seattle, WA, USA, ³Montefiore Medical Center, ⁴University of California-Los Angeles, CA, USA, ⁵Northshore University Health System, Evanston, IL, USA, ⁶Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA, ⁷Mary Crowley Cancer Research Center, Dallas, TX, USA, ⁸Virginia Cancer Specialists, Fairfax, VA, USA, ⁹Woodlands Medical Specialists – Pensacola, FL, USA, ¹⁰Mirati Therapeutics, San Diego, CA, USA, ¹¹Monoceros Biosystems, San Diego, CA, USA, ¹²University of Minnesota Masonic Cancer Center, Minneapolis, MN, USA

Society for Immunotherapy of Cancer

0103-020 Background

Mocetinostat: Class I and IV HDAC Inhibitor Immuno-supportive effects in the Tumor Microenvironment (TME)



Given the pleiotropic immune activating effects of moceotinostat, the combination of mocetinostat and the PD-L1 blocking mAb durvalumab was tested in NSCLC patients with checkpoint inhibitor therapy (CIT) naïve disease or had progressive disease after prior CIT



0103-020 Phase 2 Design

- Phase 1/2 study evaluating the tolerability and clinical activity of mocetinostat in combination with durvalumab
- ORR in accordance with RECIST 1.1 is the primary clinical benefit endpoint

&.2018

- Predictive Probability Design for assessment of enrollment expansion in each stage and treatment arm
- Phase 1- Increased doses of mocetinostat administered (50, 70, 90 mg three times weekly [TIW]) in combination with durvalumab on day 1 of each 28-day cycle

					Expand if ≥ X	
				Stage 1	Responses	Stage 2
Any Histology Checkpoint	^	No/Low PD-L1 Expression	n=9	≥1	n=8	
Receipt of			High PD-L1 Expression	n=17	≥6	n=27
for advanced Experie	Checkpoint Experienced	~	Prior Clinical Benefit	n= 9	≥1	n= 8
	(CIT-E)	\searrow	No Prior Clinical Benefit	N= 9	≥1	N= 8





0103-020 Safety: Most Frequent (≥10%) Treatment-Related (Mocetinostat and/or Durvalumab)

Adverse Event	Phase 2 Safety Population N=63		
(Preferred Term)	All Grades n (%)	Grade ≥3 n (%)	
Fatigue	25 (40)	6 (10)	
Nausea	22 (35)	1 (2)	
Diarrhea	18 (29)	2 (3)	
Decreased appetite	15 (24)	0	
Vomiting	8 (13)	0	
Fatigue	25 (40)	6 (10)	
Cardiac disorders*	5 (8)	3 (5)	

*Includes adverse events of atrial fibrillation, cardiac tamponade, pericardial effusion, and pericarditis As of 02 October 2012 – all Phase 2 patients including CIT-Experienced and CIT-Naïve.






0103-020 Clinical Activity

PRELIMINARY MAXIMUM RESPONSE IN NSCLC PATIENTS WHO FAILED PRIOR CHECKPOINT THERAPY

(Clinical Activity Evaluable Patients, N=29)





Monalizumab in combination with cetuximab in R/M SCCHN: Clinical results and preliminary biomarker analyses.

Roger B. Cohen¹,

Jérôme Fayette², Marshall Posner³, Gautier Lefebvre⁴, Jessica Bauman⁵, Sébastien Salas⁶, Caroline Even⁷, Dimitrios Colevas⁸, Antonio Jimeno⁹, Esma Saada¹⁰, Barbara Burtness¹¹, Franceline Calmels¹², Robert Zerbib¹², Agnès Boyer-Chammard¹², Pascale André¹²,Tanguy Seiwert¹³

1- Abramson Cancer Center, Philadelphia, PA; 2- Centre Léon Bérard, Lyon, France; 3- Mount Sinai Medical Center, New York, NY; 4- Oscar Lambret Institute, Lille, France; 5- Fox Case Cancer Center, Philadelphia, PA; 6- AP-HM, Marseille, France; 7- Gustave Roussy, Paris, Villejuif, France; 8- Stanford University Medical Center, Stanford, CA; 9- University of Colorado Cancer Center, Denver, CO; 10- Centre A. Lacassagne, Nice, France; 11- Yale University, New Haven, CT; 12- Innate Pharma, Marseille, France; 13- University of Chicago, IL.










Dual antibody targeting in cancer immunology

Monalizumab:

- First-in-class humanized IgG₄ targeting NKG2A on NK and tumor infiltrating CD8⁺ T cells.
- Blocks binding of CD94/NKG2A to HLA-E reducing inhibitory signaling and thereby unleashing NK and T cell responses.



Hypothesis: Dual targeting with the combination of monalizumab and cetuximab will provide greater antitumor activity than cetuximab alone.


André et al., Cell in press





IPH2201-203 study design

- Multicenter single arm study to evaluate the combination of monalizumab and cetuximab in patients with recurrent and/or metastatic SCCHN (R/M SCCHN)
- Cohort expansion in recurrent and/or metastatic SCCHN patients (NCT02643550).
- N= 40 patients enrolled. Data cut-off August 31, 2018.



* prior cetuximab allowed if for locally advanced disease with no PD for at least 4 months




Overall Response Rate is 27.5% [95% CI, 16.1-42.8]

1 confirmed CR & 10 confirmed PR $\,$

< sitc

Society for Immunotherapy of Cancer


- Responses observed in IO naive (35% [19-55]) and IO pretreated patients (18% [6-41])
- Responses observed in platinum resistant patients and in HPV positive and negative disease



Best change of tumor size from baseline

One patient with death from clinical progression before the 1st post baseline radiological assessment is not represented in the graphs





Median time to response is 1.6 months [1.5-3.9]

Csitc

Society for Immunotherapy of Cancer

Median duration of response is 5.6 months [3.8-NR*]


SITC





Safety profile of the combination

AEs related to the monalizumab cetuximab combination



- No new safety signals for monalizumab
- Only one patient stopped treatment for an AE
- No potentiation of cetuximab side effects



SITC 2019

Nov. 6-10, 2019

Gaylord National Hotel & Convention Center National Harbor, Maryland





© 2018–2019 Society for Immunotherapy of Cancer



Questions?



Mount The Tisch Cancer Institute Sinai

thomas.marron@mountsinai.org

703-609-9912



